Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 142

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 142
---
 2025 at less than the “minimum price” under Nasdaq Listing Rule 5635(d), including the issuance of equity compensation to one of our directors upon the exercise of the February 2025 Common Warrants at less than market value pursuant to Nasdaq Listing Rule 5635(c).Proposal No. 3: The approval, subject to certain conditions, of the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635 upon the conversion of the Company’s Series D convertible preferred stock, par value $0.0001 per share, issued in a private placement in April 2025, at less than the “minimum price” under Nasdaq Listing Rule 5635(d). Proposal No. 4: The approval of the CER o Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (the “Plan”), as amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional [___] shares. Proposal No. 5: The approval of the election of two Class I directors to the Board to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Nominees: A. Michael Byrnes B. Lindsey Rolfe, M.D.Proposal No. 6: The ratification of the appointment of Wolf & Company, P.C., as our independent registered public accounting firm for the 2025 fiscal year. Proposal No. 7: The approval of an adjournment of the annual meeting, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes in favor of Proposal No. 1, 2, 3 or 4.CONTROL NUMBER Signature Signature, if held jointly Date 2025. Note: Signature should agree with name printed hereon. If shares are held in the name of more than one person, EACH joint owner should sign. Executors, administrators, trustees, guardians, and attorneys should indicate the capacity in which they sign. Attorneys should submit powers of attorney. 2025 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on [ ], 2025.To view the Proxy Statement and to Attend the Annual Meeting, please go to: https://www.cstproxy.com/cero/2025 PROXY FOLD HERE DO